Company Overview

Update
Headquarters:
South San Francisco, CA
Funding:
$32.50M
Categories:
Biotechnology

Altheos was a biopharmaceutical company focused on the development of small molecule drugs.

Description

Update

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Current Team (4)

Update

Board Members and Advisors (2)

Update

Funding Rounds (2) - $32.50M

Update

Investors (5)

Update

Offices/Locations (1)

Update
  • Office

    400 Oyster Point Boulevard

    Suite 108

    South San Francisco, CA 94080

    USA